Intro
Foreword
Preface
Contents
Part I: Introduction to Elastography
1: Elastographic Measures: A Methodological Approach
1.1 Phase 0
1.2 Phase 1
1.3 Phase 2
1.4 Phase 3
1.5 Phase 4
1.6 Conclusions
References
2: Liver Stiffness: Thresholds of Health
2.1 Preamble: The Concept of Normality in Medicine
2.2 Healthy Ranges in Liver Disease Diagnostics
2.3 Definition of Healthy Ranges for Liver Stiffness
2.4 Conclusions
References
Part II: Liver Diseases

3: The Role of Transient Elastography for Fibrosis Staging in HCV-Related Chronic Liver Disease
3.1 Introduction
3.2 Assessment of Liver Disease Severity
3.2.1 Role of Liver Biopsy
3.2.2 Non-Invasive Assessment of Liver Fibrosis in CHC
3.3 Transient Elastography for the Assessment of Liver Fibrosis Prior to Antiviral Therapy
3.3.1 Combination Algorithms
3.3.2 TE vs. Other Elastography Techniques
3.4 Transient Elastography for the Assessment of Liver Fibrosis After SVR
3.5 Transient Elastography for Diagnosing Liver-Related Complications

3.5.1 Portal Hypertension
3.5.2 Gastro-Oesophageal Varices (GEV)
3.5.3 Hepatocellular Carcinoma (HCC)
3.6 Transient Elastography to Determine Prognosis
3.7 Conclusions
References
4: The Role of Elastography in HBV: Assessing Liver Fibrosis
4.1 Introduction
4.2 Liver Stiffness Cofactors and Confounders
4.3 TE in Untreated HBV Carriers
4.3.1 HBsAg Carriers Without Liver Disease
4.3.2 Untreated CHB Patients
4.4 TE in Treated CHB Patients
4.4.1 LS Kinetics During Antiviral Treatment

4.4.2 Correlation Between LS Changes During Treatment and CHB Outcomes
4.5 Conclusions
References
5: The Role of Transient Elastography in NAFLD
5.1 Fibrosis in NAFLD: The Burden
5.2 Transient Elastography: The Technique
5.2.1 The Procedure
5.2.2 Probes
5.2.3 The Role of Controlled Attenuation Parameter (CAP)
5.2.4 Limitations
5.3 Transient Elastography in NAFLD: The Quote
5.3.1 Diagnostic Accuracy
5.3.2 The Issue of Rule-In and Rule-Out
5.3.3 Confounding Factors
5.3.4 Liver Stiffness as Predictor of Liver Events
5.4 Conclusions